Abstract 247P
Background
Evaluate Role of ADC values in assessing response to chemoradiotherapy in cervix cancer & contribution of contrast MRI to identify residual disease, post-treatment completion.
Methods
Prospective observational study in 100 patients of histopathologically proven cancer of the uterine cervix. Based on clinical outcome integrating final histopathological diagnosis patients were classified as either complete response or Residual disease. Validity & reliability of PET-CT, Contrast MRI, and ADC values were checked by calculating sensitivity, specificity, PPV & NPV.
Results
Residual lesions have significantly lower ADC value than that of post-treatment changes. Mean ADC values of residual tumors: 1.26±0.238 x 10-3 mm2/s and mean ADC values of lesions due to post-treatment changes: 1.540 ±0.218 x 10-3 mm2/s (statistically significant difference in between malignant and post-treatment lesions p < 0.05). ADC sensitivity 67%, specificity 83%, PPV 35%, NPV 95 % and accuracy 81% in differentiating residual disease from post-treatment changes. PPV, NPV, sensitivity, and specificity with PET-CT was 93%, 89%, 98%, and 73%. PPV, NPV, sensitivity, and specificity of contrast MRI was 16%, 91%, 58%, and 59%.
Conclusions
Diffusion imaging differentiates residual cervix malignancies from post-treatment changes based on ADC values and can be a promising and evocative biomarker. Complimentary use of ADC and PET/CT may increase diagnostic confidence. However, the cost and logistics of MRI imaging is an important factor in routine clinical implementation especially in developing countries like India, where carcinoma cervix is associated with poor socioeconomic status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract